The DCLK1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the DCLK1 gene in a human cervical adenocarcinoma background. This polyclonal knockout model, generated through CRISPR/Cas9-mediated gene disruption, provides a heterogeneous mixture of edited cells, enabling functional interrogation of DCLK1-dependent processes without clonal selection bias.
The HeLa cell line is an extensively characterized human cervical adenocarcinoma epithelial line originally derived from the biopsy of Henrietta Lacks in 1951. This highly aneuploid cell line harbors integrated HPV18 sequences and has served as a foundational model in cancer biology for decades. Its robust proliferation, well-documented transcriptomic and proteomic profiles, and tractability for genetic manipulation make it an ideal host for studying gene function in a cancer-relevant context.
DCLK1 encodes a microtubule-associated kinase that regulates microtubule dynamics and cell migration. In cancer, DCLK1 functions as a stem cell marker and drives epithelial-mesenchymal transition (EMT) and tumor progression. Mechanistically, DCLK1 is transcriptionally activated by Wnt/??-catenin signaling through TCF/LEF transcription factors and by NF-??B and STAT3 downstream of IL-6. Once expressed, DCLK1 phosphorylates downstream targets and promotes the expression of EMT-associated transcription factors such as ZEB1, Snail, and Slug, thus facilitating a mesenchymal phenotype. DCLK1 also interacts with tubulin, 14-3-3 proteins, and Hsp90 to modulate microtubule stability and signaling. Additionally, it participates in cross-talk with Notch, Hedgehog, and PI3K/AKT pathways, converging on cancer stem cell self-renewal and KRAS-mediated signaling loops.
In the HeLa cellular context, DCLK1 knockout offers a powerful tool to dissect the kinase’s role in cervical adenocarcinoma progression. Given HeLa cells’ epithelial origin, DCLK1 disruption is expected to impair microtubule dynamics, cell migration, and invasive potential, while also affecting the expression of EMT markers and stem cell properties. This model enables the investigation of how DCLK1-mediated signaling integrates with HPV18 oncogenic programs, which may reveal novel vulnerabilities in cervical cancer. The polyclonal nature allows for assessment of functional heterogeneity and reduces artifacts from single-clone selection, providing a more physiologically relevant loss-of-function system.
This knockout product is suited for a wide range of research applications, including western blotting and immunofluorescence to confirm DCLK1 ablation and assess microtubule organization, wound healing and invasion assays to measure migratory and invasive capacity, colony formation and flow cytometry to evaluate stemness, and RT-qPCR or RNA-seq to profile EMT-associated gene expression changes. It can be employed in drug sensitivity screens targeting DCLK1-dependent pathways or in functional studies of upstream regulators and downstream effectors. For further details or technical support, please contact Ascent Research.
